Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
| Market Cap | 2.97B+11.9% |
| Revenue (ttm) | 463.98M+76.1% |
| Net Income | 28.52M+130.6% |
| EPS | 0.21+127.8% |
| Shares Out | 125.08M |
| PE Ratio | 107.61 |
| Forward PE | 17.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,724 |
| Open | 23.91 |
| Previous Close | 24.17 |
| Day's Range | 23.64 - 23.96 |
| 52-Week Range | 19.30 - 31.77 |
| Beta | 1.58 |
| Analysts | Buy |
| Price Target | 38.33(+61.32%) |
| Earnings Date | Oct 27, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ARQT
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ARQT stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of ARQT by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | May 29, 2026 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | May 29, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | May 28, 2026 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 3, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 3, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 2, 2026 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | Dec 11, 2025 |
| Gilbert CisnerosHouse / D | Sale$1.00K – $15.00K | Dec 11, 2025 |
Recently reported changes in ARQT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ARQT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ARQT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ARQT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ARQT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ARQT
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $165.25M |
| VTIVanguard Morningstar Total Stock Market ETF | $85.68M |
| XBIState Street SPDR S&P Biotech ETF | $75.67M |
| IWMiShares Russell 2000 ETF | $71.37M |
| VXFVanguard Extended Market ETF | $31.72M |
| IWOiShares Russell 2000 Growth ETF | $25.87M |
Estimated from each fund’s disclosed top holdings × AUM
ARQT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ARQT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score